Karyopharm Therapeutics, Inc. KPTI 深 滬
已收盤 02-06 16:00:00 美东时间
6.26
+0.170
+2.79%
華盛通- 最 高6.6596
- 今 開6.22
- 成交量 52.06万股
- 最 低 6.00
- 昨 收 6.09
- 總市值 1.15亿
- 52周最高 10.38
- 市盈率 靜 --
- 換手率 2.84%
- 52周最低 3.51
- 委 比 -71.23%
- 總股本 1831.03万
- 歷史最高 735.075
- 量 比 1.35
- 振 幅 10.83%
- 歷史最低 5.875
- 每 手 1
- 風險率 1.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cantor Fitzgerald Initiates Coverage On Karyopharm Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight rating.
02-05 22:45
Karyopharm Therapeutics Grants RSUs to New Employees Under Inducement Plan
Karyopharm Therapeutics Grants RSUs to New Employees Under Inducement Plan Karyopharm Therapeutics Inc. has granted a total of 1,799 restricted stock units (RSUs) to four newly hired employees. The RSUs will vest over three years, with one-third of the shares vesting on each anniversary of the grant
02-03 05:06
Kristin Abate, Chief Accounting Officer, Reports Sale of Karyopharm Therapeutics Inc. Common Shares
Kristin Abate, Chief Accounting Officer, Reports Sale of Karyopharm Therapeutics Inc. Common Shares Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This n
01-23 05:09
Karyopharm Therapeutics Narrows FY2025 Sales Guidance from $140.000M-$155.000M to $145.000M vs $147.830M Est
Karyopharm Therapeutics (NASDAQ:KPTI) narrows FY2025 sales outlook from $140.000 million-$155.000 million to $145.000 million vs $147.830 million estimate.
01-12 20:41
Karyopharm Therapeutics Sees Q4 Sales $33.000M vs $35.846M Est
Karyopharm Therapeutics (NASDAQ:KPTI) sees Q4 sales of $33.000 million vs $35.846 million analyst estimate.
01-12 20:41
Karyopharm Issues Preliminary 2025 Financial Results and Outlook
Karyopharm Therapeutics ( ($KPTI) ) has shared an update. On January 12, 2026, ...
01-12 20:35
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Jan. 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
01-03 05:05
Karyopharm to Participate in Baird's Biotech Discovery Series
NEWTON, Mass., Dec. 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
2025-12-08 20:00
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
NEWTON, Mass., Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
2025-12-01 20:00
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
